Advertisement

Human Papilloma Virus as a Biomarker for Personalized Head and Neck Cancer Radiotherapy

  • Jesper Grau EriksenEmail author
  • Pernille Lassen
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 198)

Abstract

A dramatic increase in the incidence of HPV-related oropharyngeal cancer has been reported in some parts of the western world over the past 30 years. They constitute a clinically distinct subgroup of cancers in terms of molecular biology, patient characteristics, and treatment outcome. This chapter describes the molecular characteristics, epidemiology, and demographics of the HPV-related head and neck cancers and discuss available methods to detect HPV-related tumours. The impact of HPV-related biomarkers in clinical studies on radiotherapy only, altered fractionation, modulation of hypoxia, and concurrent chemo- or bio-radiotherapy are reviewed as well as the perspectives of de-escalation and immune-modulation are discussed.

Keywords

Head and neck cancer Radiotherapy HPV P16 Hypoxia De-intensification 

References

  1. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefPubMedPubMedCentralGoogle Scholar
  2. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman E, Weber RS, Galvin JM, Schwartz DL, El-Naggar AK, Gillison ML, Jordan R, List MA, Konski AA, Thorstad A, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod R (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29:5500 ASCO meeting abtractsGoogle Scholar
  3. Attner P, Nasman A, Du J, Hammarstedt L, Ramqvist T, Lindholm J, Munck-Wikland E, Dalianis T, Marklund L (2012) Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment. Int J Cancer 131:1124–1130CrossRefPubMedGoogle Scholar
  4. Badoual C, Hans S, Merillon N, Van RC, Ravel P, Benhamouda N, Levionnois E, Nizard M, Si-Mohamed A, Besnier N, Gey A, Rotem-Yehudar R, Pere H, Tran T, Guerin CL, Chauvat A, Dransart E, Alanio C, Albert S, Barry B, Sandoval F, Quintin-Colonna F, Bruneval P, Fridman WH, Lemoine FM, Oudard S, Johannes L, Olive D, Brasnu D, Tartour E (2013) PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73:128–138CrossRefPubMedGoogle Scholar
  5. Begum S, Cao D, Gillison ML, Zahurak M, Westra WH (2005) Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 11:5694–5699CrossRefPubMedGoogle Scholar
  6. Bentzen J, Toustrup K, Eriksen JG, Primdahl H, Andersen LJ, Overgaard J (2015) Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol 54:1001–1007CrossRefPubMedGoogle Scholar
  7. Blomberg M, Nielsen A, Munk C, Kjaer SK (2011) Trends in head and neck cancer incidence in Denmark, 1978–2007: focus on human papillomavirus associated sites. Int J Cancer 129:733–741CrossRefPubMedGoogle Scholar
  8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578CrossRefPubMedGoogle Scholar
  9. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28CrossRefPubMedGoogle Scholar
  10. Braakhuis BJ, Snijders PJ, Keune JWH, Meijer CJ, Ruijter-Schippers HJ, Leemans R, Brakenhoff RH (2004) Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer 96:998–1006CrossRefGoogle Scholar
  11. Brun JL, Dalstein V, Leveque J, Mathevet P, Raulic P, Baldauf JJ, Scholl S, Huynh B, Douvier S, Riethmuller D, Clavel C, Birembaut P, Calenda V, Baudin M, Bory JP (2011) Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am J Obstet Gynecol 204:169.e1–169.e8CrossRefGoogle Scholar
  12. Burk RD, Chen Z, Van DK (2009) Human papillomaviruses: genetic basis of carcinogenicity. Pub Health Gen 12:281–290CrossRefGoogle Scholar
  13. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML (2008) Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26:612–619CrossRefPubMedGoogle Scholar
  14. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao E, Kin E, Jiang B, Goodman MT, Siburg-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294–4301CrossRefPubMedPubMedCentralGoogle Scholar
  15. Chung CH, Gillison ML (2009) Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 15(22):6758–6762CrossRefPubMedGoogle Scholar
  16. Dobrosotskaya IY, Bellile E, Spector ME, Kumar B, Feng F, Eisbruch A, Wolf GT, Prince ME, Moyer JS, Teknos T, Chepeha DB, Walline HM, McHugh JB, Cordell KG, Ward PD, Byrd S, Maxwell JH, Urba S, Bradford CR, Carey TE, Worden FP (2014) Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV positive and HPV negative locally advanced squamous cell carcinoma of the oropharynx (SCCOP). Head Neck 36:617–623CrossRefPubMedGoogle Scholar
  17. Doorbar J (1979) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006(110):525–541Google Scholar
  18. Doorbar J (2005) The papillomavirus life cycle. J Clin Virol 32(Suppl 1):S7–S15CrossRefPubMedGoogle Scholar
  19. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML (2007) Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 356:1944–1956CrossRefPubMedGoogle Scholar
  20. El-Naggar AK, Westra WH (2012) p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 34:459–461CrossRefPubMedGoogle Scholar
  21. Eriksen JG, Steiniche T, Alsner J, Askaa J, Overgaard J (2004) The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 58:561–566CrossRefPubMedGoogle Scholar
  22. Eriksen JG, Lassen P, Overgaard J (2010) Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab? Lancet Oncol 11:312–313CrossRefPubMedGoogle Scholar
  23. Fakhry C, Gillison ML (2006) Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606–2611CrossRefPubMedPubMedCentralGoogle Scholar
  24. Friesland S, Mellin H, Munck-Wikland E, Nilsson A, Lindholm J, Dalianis T, Lewensohn R (2001) Human papilloma virus (HPV) and p53 immunostaining in advanced tonsillar carcinoma—relation to radiotherapy response and survival. Anticancer Res 21:529–534PubMedGoogle Scholar
  25. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720CrossRefPubMedGoogle Scholar
  26. Gillison ML, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420CrossRefPubMedGoogle Scholar
  27. Gillison ML, Snijders PJ, Chaturvedi AK, Steinberg BM, Schwartz S, Castellsague X (2012a) Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 30(Suppl 5):F34–F54CrossRefPubMedGoogle Scholar
  28. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, Graubard BI, Chaturvedi AK (2012b) Prevalence of oral HPV infection in the United States, 2009–2010. JAMA 307:693–703CrossRefPubMedGoogle Scholar
  29. Hammarstedt L, Dahlstrand H, Lindquist D, Onelöv L, Ryott M, Luo J, Dalianis T, Ye W, Munck-Wikland E (2007) The incidence of tonsillar cancer in Sweden is increasing. Acta oto-laryngol 127:988–992CrossRefGoogle Scholar
  30. Huang SH, Perez-Ordonez B, Liu FF, Waldron J, Ringash J, Irish J, Cummings B, Siu LL, Kim J, Weinreb I, Hope A, Gullane P, Brown D, Shi W, O’Sullivan B (2010) Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy. Int J Radiat Oncol Biol Phys 82:276–283CrossRefPubMedGoogle Scholar
  31. Isayeva T, Maswahu D, Brandwein-Gensler M (2012) Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol 6(Suppl 1):S104–S120CrossRefPubMedGoogle Scholar
  32. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffmann M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK (2013) Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer 105:175–201CrossRefGoogle Scholar
  33. Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML (2012) Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36:945–954CrossRefPubMedGoogle Scholar
  34. Khleif SN (1996) Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. PNAS 93:4350–4354CrossRefPubMedPubMedCentralGoogle Scholar
  35. Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomark Prev 14:467–475CrossRefGoogle Scholar
  36. Lassen P (2010) The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 95:371–380CrossRefPubMedGoogle Scholar
  37. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J (2009) Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 27:1992–1998CrossRefPubMedGoogle Scholar
  38. Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J (2010) HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 94:30–35CrossRefPubMedGoogle Scholar
  39. Lassen P, Eriksen JG, Krogdahl A, Therkildsen MH, Ulhoi BP, Overgaard M, Specht L, Andersen E, Johansen J, Andersen LJ, Grau C, Overgaard J (2011) The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 100:49–55CrossRefPubMedGoogle Scholar
  40. Lassen P, Overgaard J, Eriksen JG (2013) Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. Radiother Oncol 108:489–494CrossRefPubMedGoogle Scholar
  41. Lau HY, Brar S, Klimowicz AC, Petrillo SK, Hao D, Brockton NT, Kong CS, Lees-Miller SP, Magliocco AM (2011) Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. Head Neck 33:251–256CrossRefPubMedGoogle Scholar
  42. Lewis JS (2012) p16 immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol 6(Suppl 1):S75–S82CrossRefPubMedGoogle Scholar
  43. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantu G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630–5636CrossRefPubMedGoogle Scholar
  44. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM (2001) Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 92:805–813CrossRefPubMedGoogle Scholar
  45. Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, Perez-Ordonez B, Jordan RC, Gillison ML (2013) Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 49:1–8CrossRefPubMedGoogle Scholar
  46. Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789CrossRefPubMedGoogle Scholar
  47. Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S (2013) Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer-systematic review and meta-analysis of trends by time and region. Head Neck 35:747–755CrossRefPubMedGoogle Scholar
  48. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E (2000) Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89:300–304CrossRefPubMedGoogle Scholar
  49. Mellin DH, Lindquist D, Bjornestal L, Ohlsson A, Dalianis T, Munck-Wikland E, Elmberger G (2005) P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 25:4375–4383Google Scholar
  50. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sorensen BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J (2012) FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 105:14–20CrossRefPubMedGoogle Scholar
  51. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10(7):699–703CrossRefPubMedGoogle Scholar
  52. O’Sullivan B, Huang SH, Perez-Ordonez B, Massey C, Siu LL, Weinreb I, Hope A, Kim J, Bayley AJ, Cummings B, Ringash J, Dawson LA, Cho BC, Chen E, Irish J, Gilbert RW, Hui A, Liu FF, Zhao H, Waldron JN, Xu W (2012) Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation. Radiother Oncol 103:49–56CrossRefPubMedGoogle Scholar
  53. O’Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W (2013) Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 31:543–550CrossRefPubMedGoogle Scholar
  54. Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. Radiother Oncol 100:22–32CrossRefPubMedGoogle Scholar
  55. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindelov B, Jorgensen K (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46:135–146CrossRefPubMedGoogle Scholar
  56. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933–940CrossRefPubMedGoogle Scholar
  57. Pajares B, Trigo JM, Toledo MD, Alvarez M, Gonzalez-Hermoso C, Rueda A, Medina JA, Luque V, Jerez JM, Alba E (2013) Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer 13:26CrossRefPubMedPubMedCentralGoogle Scholar
  58. Pignon JP, Le MA, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMedGoogle Scholar
  59. Ragin CC, Taioli E (2007) Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121:1813–1820CrossRefPubMedGoogle Scholar
  60. Rieckmann T, Tribius S, Grob TJ, Meyer F, Busch CJ, Petersen C, Dikomey E, and Kriegs M (2013) HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol S0167–S8140Google Scholar
  61. Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, Solomon B, Choi J, O’Sullivan B, Kenny LM, McArthur GA (2010a) Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28:4142–4148CrossRefPubMedPubMedCentralGoogle Scholar
  62. Rischin D, Peters LJ, O’Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L (2010b) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28:2989–2995CrossRefPubMedGoogle Scholar
  63. Settle K, Posner MR, Schumaker LM, Tan M, Suntharalingam M, Goloubeva O, Strome SE, Haddad RI, Patel SS, Cambell EV III, Sarlis N, Lorch J, Cullen KJ (2009) Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res 2:776–781CrossRefGoogle Scholar
  64. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, O’Sullivan B, Waldron J, Cummings B, Kim J, Ringash J, Dawson LA, Gullane P, Siu L, Gillison M, Liu FF (2009) Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27:6213–6221CrossRefPubMedGoogle Scholar
  65. Slebos RJ, Yi Y, Ely K, Carter J, Evjen A, Zhang X, Shyr Y, Murphy BA, Cmelak AJ, Burkey BB, Netterville J, Levy S, Yarbrough WG, Chung CH (2006) Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 12:701–709CrossRefPubMedGoogle Scholar
  66. Smeets SJ, Braakhuis BJ, Abbas S, Snijders PJ, Ylstra B, van de Wiel MA, Meijer GA, Leemans CR, Brakenhoff RH (2006) Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25:2558–2564CrossRefPubMedGoogle Scholar
  67. Smeets SJ, Hesselink AT, Speel EJ, Haesevoets A, Snijders PJ, Pawlita M, Meijer CJ, Braakhuis BJ, Leemans CR, Brakenhoff RH (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121:2465–2472CrossRefPubMedGoogle Scholar
  68. Smith EM, Ritchie JM, Summersgill KF, Klussmann JP, Lee JH, Wang D, Haugen TH, Turek LP (2004) Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004(108):766–772CrossRefGoogle Scholar
  69. Sorensen BS, Busk M, Olthof N, Speel EJ, Horsman MR, Alsner J, Overgaard J (2013) Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells. Radiother Oncol S0167–S8140Google Scholar
  70. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Shefler E, Stojanov P, Carter S, Voet D, Auclair D, Berger MF, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Ardlie K, Gabriel BS, Meyerson M, Lander ES, Getz G, Grandis JR (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157–1160CrossRefPubMedPubMedCentralGoogle Scholar
  71. Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Görner M, Stanley M, Goon PKC (2011) Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol 268:1541–1547CrossRefPubMedGoogle Scholar
  72. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454CrossRefPubMedPubMedCentralGoogle Scholar
  73. Toustrup K, Sorensen BS, Lassen P, Wiuf C, Alsner J, Overgaard J (2012) Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 102:122–129CrossRefPubMedGoogle Scholar
  74. Wansom D, Light E, Worden F, Prince M, Urba S, Chepeha DB, Cordell K, Eisbruch A, Taylor J, D’Silva N, Moyer J, Bradford CR, Kurnit D, Kumar B, Carey TE, Wolf GT (2010) Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 136:1267–1273CrossRefPubMedPubMedCentralGoogle Scholar
  75. Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A (2006) Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736–747CrossRefPubMedGoogle Scholar
  76. Westra WH (2012) The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head Neck Pathol 6(Suppl 1):S48–S54CrossRefPubMedGoogle Scholar
  77. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, Urba SG, Eisbruch A, Teknos TN, Chepeha DB, Prince ME, Tsien CI, D’Silva NJ, Yang K, Kurnit DM, Mason HL, Miller TH, Wallace NE, Bradford CR, Carey TE (2008) Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol 26:3138–3146CrossRefPubMedPubMedCentralGoogle Scholar
  78. Zur Hausen H (1994) Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr top microbiol immunol 186:131–156PubMedGoogle Scholar
  79. Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev Cancer 2:342–350CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  1. 1.Department of OncologyOdense University HospitalOdenseDenmark
  2. 2.Department of Oncology, Department of Clinical Experimental OncologyAarhus University HospitalAarhus CDenmark

Personalised recommendations